Effects of caffeine on people suffering from intermittens claudication. Three double blinded, placebo-controlled cross-over studies and a follow-up study. - Caffeine and intermittens claudicatio

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-001902-10-DK

Enrollment

Unknown

Registered

2006-05-11

Start date

2006-05-31

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intermittens claudication, peripheral arterial disease (PAD) Atherosclerotic disease of the lower extremities

Interventions

Product Name: caffeine Pharmaceutical Form: Capsule, hard Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150, 200, 250- Pharmaceutical form of the placebo: Capsule

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: intermittens claudicatio, mild, moderate grade (Fontaine II) ancle-brachial systolic blood pressure index =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Dementia, Diabetes, Weigth >100kg, Medical treatment with: Theofyllamin, Trental

Design outcomes

Primary

Measure	Time frame
Main Objective: Physical performance: Longer maximum walking distance, higher lever of VGF, FGF- factors ;Secondary Objective: quality of life after surgical operation longer painfree walking distance strength, balance, reaction, cognitive function ;Primary end point(s): Maximum Walking Distance (MWD) Raised level of VGF, FGF-Endothelial Growth FactorS Painfree Walking Distance (PWD) Quality of life (QOL) Less Walking Impairment Better physical and cognitive performance	—

Measure

Time frame

Main Objective: Physical performance: Longer maximum walking distance, higher lever of VGF, FGF- factors ;Secondary Objective: quality of life after surgical operation longer painfree walking distance strength, balance, reaction, cognitive function ;Primary end point(s): Maximum Walking Distance (MWD) Raised level of VGF, FGF-Endothelial Growth FactorS Painfree Walking Distance (PWD) Quality of life (QOL) Less Walking Impairment Better physical and cognitive performance

—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026